Genomic and epigenetic instability in colorectal cancer

Iranian Journal of Cancer Prevention

Volumn 6, Issue SUPPL.1, 2013, Pages

  Safaei, Akram ^a   Sobhi, Sara ^a   Rezaei Tavirani, Mostafa ^b   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Epigenomics; Genetic

Indexed keywords

APC PROTEIN; B RAF KINASE; FAS ANTIGEN; HISTONE H3; MICRORNA; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN P53; RAD50 PROTEIN; SMAD2 PROTEIN; SMAD4 PROTEIN; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; VIMENTIN;

ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL INSTABILITY; CHROMOSOME 18; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COLORECTAL CANCER; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETIC INSTABILITY; EPIGENETICS; GENE ACTIVATION; GENE CONTROL; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; GENETIC VARIABILITY; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HISTONE MODIFICATION; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 84875284665     PISSN: 20082401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA: a cancer journal for clinicians. 2010;60[2]:99-119.
2. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149[7]:441-450.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100[1]:57-70.
4. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science Signalling. 2007;318[5853]:1108.
5. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annual Review of Pathological Mechanical Disease. 2009;4:343-364.
6. Issaq HJ, Blonder J. Electrophoresis and liquid chromatography/tandem mass spectrometry in disease biomarker discovery. Journal of Chromatography B. 2009;877[13]:1222-1228.
7. Kumar S, Mohan A, Guleria R. Biomarkers in cancer screening, research and detection: present and future: a review. Biomarkers. 2006 Sep- Oct;11[5]:385-405.
8. Fleming N, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer research. 2012.
9. Abdul Murad NA, Othman Z, Khalid M, Abdul Razak Z, Hussain R, Nadesan S, et al. Missense Mutations in MLH1, MSH2, KRAS, and APC Genes in Colorectal Cancer Patients in Malaysia. Digestive Diseases and Sciences.1-10.
10. Je EM, Lee SH, Yoo NJ. Somatic mutation of a tumor suppressor gene BAP1 is rare in breast, prostate, gastric and colorectal cancers. Apmis. 2012.
11. Von Holst S, Picelli S, Edler D, Lenander C, Dalén J, Hjern F, et al. Association studies on 11 published colorectal cancer risk loci. British journal of cancer. 2010;103[4]:575-80.
12. Vogelstein B, Fearon E, Hamilton S. Genetic alterations during colorectal-tumor development. Journal of Occupational and Environmental Medicine. 1989;31[10]:815.
13. Derynck R, Akhurst RJ, Balmain A. TGF-D signaling in tumor suppression and cancer progression. Nature genetics. 2001;29[2]:117-129.
14. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-basedsample.PLoSOne. 2008;3[11]:e3698.
15. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129[3]:837.
16. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24. 21. Nature Genetics. 2007;39[8]:984-8.
17. Tomlinson IPM, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23. 3. Nature Genetics. 2008;40[5]:623-30.
18. Zanke BW, Greenwood CMT, Rangrej J, Kustra R, Tenesa A, Farrington SM, et al. Genome- wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nature Genetics. 2007;39[8]:989-994.
19. Kupfer SS, Anderson JR, Hooker S, Skol A, Kittles RA, Keku TO, et al. Genetic heterogeneity in colorectal cancer associations between African and European Americans. Gastroenterology. 2010;139[5]:1677-1685. e8.
20. Tenesa A, Farrington SM, Prendergast JGD, Porteous ME, Walker M, Haq N, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nature Genetics. 2008;40[5]:631-637.
21. Pittman AM, Webb E, Carvajal-Carmona L, Howarth K, Di Bernardo MC, Broderick P, et al. Refinement of the basis and impact of common 11q23. 1 variation to the risk of developing colorectal cancer. Human molecular genetics. 2008;17[23]:3720-3727.
22. Tuupanen S, Niittymäki I, Nousiainen K, Vanharanta S, Mecklin JP, Nuorva K, et al. Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution. Cancer research. 2008;68[1]:14-17.
23. Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, et al. The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nature Genetics. 2009;41[8]:885-890.
24. Jaeger E, Webb E, Howarth K, Carvajal- Carmona L, Rowan A, Broderick P, et al. Common genetic variants at the CRAC1 [HMPS] locus on chromosome 15q13. 3 influence colorectal cancer risk. Nature Genetics. 2007;40[1]:26-8.
25. Thompson CL, Plummer SJ, Acheson LS, Tucker TC, Casey G, Li L. Association of common genetic variants in SMAD7 and risk of colon cancer. Carcinogenesis. 2009;30[6]:982-986.
26. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nature Genetics. 2008;40[12]:1426-1435.
27. Safaei A, Karimi K, Arkani M, Rostami F, Arbabi E, Vahedi M, et al. Association of adiponectin gene [rs 2241766] polymorphism and colorectal cancer in Tehran, Iran. Medical Science Journal of Islamic Azad Univesity-Tehran Medical Branch. 2012;22[2]:110-5.
28. Arkani M, Safaei A, Karimi K, Arbabi E, Rostami F, Iman M, et al. Association of the insulin gene polymorphism and colorectal cancer. Koomesh. 2012;13[2]:172-176.
29. Arkani M, Safaei A, Karimi K, Vahedi M, Mohebi SR, Fatemi SR, et al. Association of IGF-1 gene [rs5742612] polymorphism with colorectal cancer. Journal of Sabzevar University of Medical Sciences. 2012;19[2]:109-115.
30. Aaltonen LA, Peltomäki P, Mecklin JP, Järvinen H, Jass JR, Green JS, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer research. 1994;54[7]:1645-1648.
31. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138[6]:2073-2087. e3.
32. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nature Reviews Clinical Oncology. 2010;7[3]:153-162.
33. Söreide K, Janssen E, Söiland H, Körner H, Baak J. Microsatellite instability in colorectal cancer. British journal of surgery. 2006;93[4]:395-406.
34. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science [New York, NY]. 1993;260[5109]:812.
35. Duval A, Hamelin R. Mutations at Coding Repeat Sequences in Mismatch Repair-deficient Human Cancers Toward a New Concept of Target Genes for Instability. Cancer research. 2002;62[9]:2447-2454.
36. Aust DE, Terdiman JP, Willenbucher RF, Chang CG, MolinaroDClark A, Baretton GB, et al. The APC/DDcatenin pathway in ulcerative colitis- relatedcolorectal carcinomas.Cancer. 2002;94[5]:1421-1427.
37. Moghbeli M, Moaven O, Dadkhah E, Farzadnia M, Roshan N, Asadzadeh-Aghdaee H, et al. High frequency of microsatellite instability in sporadic colorectal cancer patients in Iran. Genetics and Molecular Research. 2011;10[4]:3520-3529.
38. Grady WM. Genomic instability and colon cancer. Cancer and Metastasis Reviews. 2004;23[1]:11-27.
39. Lurje G, Zhang W, Lenz HJ. Molecular prognostic markers in locally advanced colon cancer. Clinical colorectal cancer. 2007;6[10]:683-690.
40. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Diseases of the colon & rectum. 1998;41[8]:1033-1049.
41. Shankaran V, Wisinski KB, Mulcahy MF, Benson AB. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Molecular Diagnosis & Therapy. 2008;12[2]:87-98.
42. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of Clinical Oncology. 2006;24[33]:5313-5527.
43. Nakao M, Kawauchi S, Furuya T, Uchiyama T, Adachi J, Okada T, et al. Identification of DNA copy number aberrations associated with metastases of colorectal cancer using array CGH profiles. Cancer genetics and cytogenetics. 2009;188[2]:70-76.
44. Sandberg AA, Meloni-Ehrig AM. Cytogenetics and genetics of human cancer: methods and accomplishments. Cancer genetics and cytogenetics. 2010;203[2]:102-126.
45. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138[6]:2059-2072.
46. Knösel T, Petersen S, Schwabe H, Schlüns K, Stein U, Schlag P, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Archiv. 2002;440[2]:187-194.
47. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New England Journal of Medicine. 2001;344[16]:1196-1206.
48. Alberici P, Fodde R. The role of the APC tumor suppressor in chromosomal instability. 2006.
49. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. Journal of Clinical Oncology. 2009;27[27]:4591-4598.
50. Nakazawa T, Kondo T, Ma D, Niu D, Mochizuki K, Kawasaki T, et al. Global histone modification of histone H3 in colorectal cancer and its precursor lesions. Human pathology. 2012;43[6]:834-842.
51. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31[1]:27-36.
52. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nature genetics. 2004;36[4]:417-422.
53. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell research. 2011;21[3]:502-517.
54. Schuebel KE, Chen W, Cope L, Glöckner SC, Suzuki H, Yi JM, et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS genetics. 2007;3[9]:e157.
55. Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011;117[9]:1847-1854.
56. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. Journal of Biomedicine and Biotechnology. 2011;2011.
57. Najjar Sadeghi R, Zojaji H, Mohebbi SR, Chiani M, Vahedi M, Mirsattari D, et al. Evaluation of global genome methylation in gastritis lesion and its correlation with clinicopatological findings. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 2009;17[11-12]:11-12.
58. Ying J, Poon F, Yu J, Geng H, Wong A, Qiu G, et al. DLEC1 is a functional 3p22. 3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. British journal of cancer. 2009;100[4]:663-669.
59. Ramirez N, Bandres E, Navarro A, Pons A, Jansa S, Moreno I, et al. Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions. European Journal of Cancer. 2008;44[17]:2689-2695.
60. An B, Kondo Y, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, et al. Characteristic methylation profile in CpG island methylator phenotypeD negative distal colorectal cancers. International Journal of Cancer. 2010;127[9]:2095-2105.
61. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nature Reviews Gastroenterology and Hepatology. 2011.
62. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, Sontag S, et al. Improved fecal DNA test for colorectal cancer screening. Clinical Gastroenterology and Hepatology. 2007;5[1]:111-117.
63. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. The Americanjournal of gastroenterology. 2008;103[11]:2862-2870.
64. Jenuwein T, Allis CD. Translating the histone code. Science Signalling. 2001;293[5532]:1074.
65. Esteller M. Epigenetics in cancer. New England Journal of Medicine. 2008;358[11]:1148-1159.
66. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science Signalling. 2005;309[5740]:1519.
67. Matsubara N. Epigenetic regulation and colorectal cancer. Diseases of the Colon & Rectum. 2012;55[1]:96.
68. Mazón Peláez I, Kalogeropoulou M, Ferraro A, Voulgari A, Pankotai T, Boros I, et al. Oncogenic RAS alters the global and gene-specific histone modification pattern during epithelial- mesenchymal transition in colorectal carcinoma cells. The International Journal of Biochemistry & Cell Biology. 2010;42[6]:911-920.
69. Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer research. 2008;68[8]:2708-2716.
70. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JCY, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2D-deoxycytidine. Cancer research. 2002;62[22]:6456-6461.
71. Valk-Lingbeek ME, Bruggeman SWM, van Lohuizen M. Stem cells and cancer: the polycomb connection. Cell. 2004;118[4]:409-418.
72. Yun J, Johnson JL, Hanigan CL, Locasale JW. Interactions between epigenetics and metabolism in cancers. Frontiers in Oncology. 2012;2.
73. Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. International Journal of Cancer. 2006;119[8]:1850-1857.
74. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature. 2000;406[6799]:1009-1012.
75. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science Signalling. 2002;296[5573]:1646.
76. Mercer KE, Pritchard CA. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochimica et Biophysica Acta [BBA]-Reviews on Cancer. 2003;1653[1]:25-40.
77. Bronner C, Baker S, Morrison P, Warren G, Smith L, Lescoe M, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is. Nature. 1994;368[6468]:258-261.
78. Baker SM, Bronner CE, Zhang L, Plug AW, Robatzek M, Warren G, et al. Male mice defective in the DNA mismatch repair gene< i> PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell. 1995;82[2]:309-19.
79. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews Cancer. 2004;4[7]:505-518.
80. Miller JR, Hocking AM, Brown JD, Moon RT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene. 1999;18[55]:7860.
81. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. The Journal of experimental medicine. 1994;179[3]:873-879.
82. Hopfner K-P, Karcher A, Shin DS, Craig L, Arthur LM, Carney JP, et al. Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily. Cell. 2000;101[7]:789-800.
83. Zaphiropoulos PG, Gailani MR, Vorechovsky I, Holmberg E, Smyth I, Pressman C, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841-851.
84. Whitman M. Smads and early developmental signaling by the TGFD superfamily. Genes & development. 1998;12[16]:2445-2462.
85. Alcantara S, Ruiz M, De Castro F, Soriano E, Sotelo C. Netrin 1 acts as an attractive or as a repulsive cue for distinct migrating neurons during the development of the cerebellar system. Development. 2000;127[7]:1359-1372.
86. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. Genes & development. 2007;21[1]:49-54.
87. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling [SOCS] proteins in regulation of the immune response. Annu Rev Immunol. 2004;22:503-529.
88. Philippova M, Ivanov D, Tkachuk V, Erne P, Resink T. Polarisation of T-cadherin to the leading edge of migrating vascular cells in vitro: a function in vascular cell motility? Histochemistry and cell biology. 2003;120[5]:353-60.
89. Bae S-C, Choi J-K. Tumor suppressor activity of RUNX3. Oncogene. 2004;23[24]:4336-4340.
90. Xu S, Jia Z-F, Kang C, Huang Q, Wang G, Liu X, et al. Upregulation of SEPT7 gene inhibits invasion of human glioma cells. Cancer investigation. 2010;28[3]:248-58.
91. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 2007;39[3]:305-18.
92. Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. World journal of surgery. 2009;33[4]:638-46.
93. Wu WKK, Law PTY, Lee CW, Cho CH, Fan D, Wu K, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis. 2011;32[3]:247-53.
94. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR- 145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72[5-6]:397-402.
95. Ng EKO, Chong WWS, Jin H, Lam EKY, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58[10]:1375-1381.
96. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clinical cancer research. 2006;12[7]:2014-2024.
97. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics-Proteomics. 2006;3[5]:317-324.
98. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced Accumulation of Specific MicroRNAs in Colorectal Neoplasia11Note: Susan M. O'Connor and Nicholas G. van Holst Pellekaan contributed equally to this work. Molecular Cancer Research. 2003;1[12]:882-891.
99. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, et al. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Molecular cancer therapeutics. 2010;9[12]:3396-3409.
100. Faber C, Kirchner T, Hlubek F. The impact of microRNAs on colorectal cancer. Virchows Archiv. 2009;454[4]:359-367.